瑞康医药
(002589)
| 流通市值：38.92亿 | | | 总市值：42.88亿 |
| 流通股本：13.66亿 | | | 总股本：15.05亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 3,543,520,195.09 | 1,756,650,456.75 | 7,966,345,576.74 | 6,056,194,532.51 |
| 营业收入 | 3,543,520,195.09 | 1,756,650,456.75 | 7,966,345,576.74 | 6,056,194,532.51 |
| 二、营业总成本 | 3,627,527,911.6 | 1,764,616,859.72 | 8,019,365,853.25 | 5,997,705,441.86 |
| 营业成本 | 3,166,861,738.37 | 1,513,399,174.43 | 7,090,142,842.63 | 5,265,530,452.49 |
| 税金及附加 | 15,698,411.4 | 9,490,020.92 | 36,911,093.36 | 26,800,898.1 |
| 销售费用 | 181,812,208.2 | 83,688,140.77 | 360,488,816.84 | 275,357,168.85 |
| 管理费用 | 170,158,323.23 | 105,913,581.75 | 394,898,420.55 | 293,252,275.18 |
| 研发费用 | 11,198,402.43 | 2,954,283.92 | 10,029,115.45 | 7,566,022.65 |
| 财务费用 | 81,798,827.97 | 49,171,657.93 | 126,895,564.42 | 129,198,624.59 |
| 其中:利息费用 | 117,884,999.14 | 75,530,939.35 | 193,866,434.08 | 166,706,929.51 |
| 其中:利息收入 | 41,992,173.82 | 31,600,653.3 | 87,891,880.27 | 59,335,714.37 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -890,896.12 | -890,896.12 | 30,647,078.86 | 12,464,457.63 |
| 加:投资收益 | 12,404,896.21 | 5,233,028.06 | 96,213,121.33 | 29,014,904.55 |
| 资产处置收益 | 173,176.52 | -92,101.14 | 18,938,795.04 | -6,467,871.93 |
| 资产减值损失(新) | - | - | 0 | 708,089.19 |
| 信用减值损失(新) | 53,240,838.15 | 27,180,110.18 | -69,614,649.77 | -42,741,474.43 |
| 其他收益 | 260,857.77 | 215,831.84 | 2,368,696.35 | 1,869,258.5 |
| 四、营业利润 | -18,818,843.98 | 23,679,569.85 | 25,532,765.3 | 53,336,454.16 |
| 加:营业外收入 | 4,491,752.35 | 434,213.66 | 20,336,749.52 | 1,850,298.04 |
| 减:营业外支出 | 1,058,168.26 | 721,816.93 | 4,300,677.24 | 8,072,922.87 |
| 五、利润总额 | -15,385,259.89 | 23,391,966.58 | 41,568,837.58 | 47,113,829.33 |
| 减:所得税费用 | -45,990,301.77 | 3,956,590.71 | 551,027.32 | -5,135,191.98 |
| 六、净利润 | 30,605,041.88 | 19,435,375.87 | 41,017,810.26 | 52,249,021.31 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 30,605,041.88 | 19,435,375.87 | 41,017,810.26 | 52,249,021.31 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 18,166,445.28 | 14,171,093.11 | 20,621,581.94 | 38,806,313.59 |
| 少数股东损益 | 12,438,596.6 | 5,264,282.76 | 20,396,228.32 | 13,442,707.72 |
| 扣除非经常损益后的净利润 | 2,899,545.5 | 10,033,796.54 | -128,320,870.87 | 8,276,900.24 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.01 | 0.01 | 0.01 | 0.03 |
| (二)稀释每股收益 | 0.01 | 0.01 | 0.01 | 0.03 |
| 九、综合收益总额 | 30,605,041.88 | 19,435,375.87 | 41,017,810.26 | 52,249,021.31 |
| 归属于母公司股东的综合收益总额 | 18,166,445.28 | 14,171,093.11 | 20,621,581.94 | 38,806,313.59 |
| 归属于少数股东的综合收益总额 | 12,438,596.6 | 5,264,282.76 | 20,396,228.32 | 13,442,707.72 |
| 公告日期 | 2025-08-26 | 2025-04-30 | 2025-04-24 | 2024-10-31 |
| 审计意见(境内) | | | 标准无保留意见 | |